The AXL-EGFR interaction mediated the process and promoted the antitumor effect of the PI3Kα inhibitor BYL719.295,296 Ribociclib is a specific CDK4/6 inhibitor that showed a synergistic effect in combination with BYL719 in nonkeratinizing NPC.297 IGF2 inhibitors enhanced the efficacy of BYL719 and taselisib (GDC0032) for the treatment of HPV-positive HNSCC. The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.